SEC Form 4 · accession 0001140361-15-021770
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Officer — Chief Executive Officer · Director
Period of report
May 21, 2015
Accepted (ET)
May 26, 2015 · 7:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 21, 2015 | S | 1,500 | $126.1047 | A | 31,758 | I | Shares held by Bienaime Family Trust |
| Common Stock | holding | — | — | — | 235,894 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Trade mad pursuant to a 10b5-1 plan executed March 2, 2015.
- F2The price in column 4 is a weighted average price. The price actually received ranged from $124.79 to $127.47. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the ranger.